Aclaris Therapeutics - ACRS Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRS shares.
View ACRS analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 1-year price targets for Aclaris Therapeutics' stock. Their ACRS share price forecasts range from $25.00 to $32.00. On average, they predict the company's stock price to reach $28.67 in the next twelve months. This suggests a possible upside of 64.0% from the stock's current price.
View analysts price targets for ACRS or view top-rated stocks among Wall Street analysts.

Aclaris Therapeutics' stock was trading at $15.75 at the beginning of the year. Since then, ACRS shares have increased by 11.0% and is now trading at $17.48.
View the best growth stocks for 2023 here.

Aclaris Therapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 2,840,000 shares, a decline of 5.0% from the December 31st total of 2,990,000 shares. Based on an average trading volume of 349,100 shares, the days-to-cover ratio is currently 8.1 days. Currently, 5.5% of the shares of the stock are short sold.
View Aclaris Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ACRS earnings forecast.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its quarterly earnings data on Tuesday, November, 8th. The biotechnology company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.09. The biotechnology company had revenue of $19.02 million for the quarter, compared to analyst estimates of $1.61 million. Aclaris Therapeutics had a negative net margin of 349.26% and a negative trailing twelve-month return on equity of 39.41%.

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX).

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Aclaris Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.10%) and Strs Ohio (0.05%). Insiders that own company stock include Andrew N Schiff, David N Gordon, Frank Ruffo, Joseph Monahan, Kamil Ali-Jackson and Neal Walker.
View institutional ownership trends.

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACRS stock can currently be purchased for approximately $17.48.

Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $1.17 billion and generates $6.76 million in revenue each year. The biotechnology company earns $-90,860,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344.